DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma

Sorafenib is the first-line therapeutic regimen targeting against advanced or metastatic stage of hepatocellular carcinoma (HCC). However, HCC patients at these stages will eventually fail sorafenib treatment due to the drug resistance. At present, molecular mechanisms underlying sorafenib resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Yang, Guohua, Guo, Xiaohong, Zhang, Jing, Sun, Wei, Liu, Dongbo, Wang, Hui, Liu, Shunfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236769/
https://www.ncbi.nlm.nih.gov/pubmed/35770048
http://dx.doi.org/10.1155/2022/2543220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236769/
https://www.ncbi.nlm.nih.gov/pubmed/35770048
http://dx.doi.org/10.1155/2022/2543220

Ejemplares similares